Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer

Drugs of Today

Volumn 35, Issue 12, 1999, Pages 931-946

  Albanell, Joan ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; METASTASIS; MULTICENTER STUDY; MYOCARDIAL DISEASE; ONCOGENE NEU; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

EID: 0033368153     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Bishop, J.M. Molecular themes in oncogenesis. Cell 1991, 64: 235-48.
2. Aaronson, S.A. Growth factors and cancer. Science 1991, 254: 1146-53.
3. Press, M.F., Cordon-Cardo, C., Slamon, D.J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5: 953-62.
4. Gullick, W.J. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer 1990, 5: 55-61.
5. Coussens, L., Yang-Feng, T.L., Liao, Y.C. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230: 1132-9.
6. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1981, 235: 177-82.
7. Press, M.F., Bernstein, L., Thomas, P.A. et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15: 2894-904.
8. Ross, J.S., Fletcher, J.A. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor and target for therapy. Oncologist 1998, 3: 237-52.
9. Slamon, D.J., Godolphin, W., Jones, L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244: 707-12.
10. Hudziak, R.M., Schlessinger, J., Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cell. Proc Natl Acad Sci USA 1987, 84: 7159-63.
11. Di Fiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., Aaronson, S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237: 178-82.
12. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A., Greene, M.I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41: 695-706.
13. Drebin, J.A., Link, V.C., Weinberg, R.A., Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986, 83: 9129-33.
14. Baselga, J., Norton, L., Albanell, J., Kim, Y.M., Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58: 2825-31.
15. Lewis, G.D., Figari, I., Fendly, B. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37: 255-63.
16. Shepard, H.M., Lewis, G.D., Sarup, J.C. et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 1991, 11: 117-27.
17. Hynes, N.E., Stern, D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198: 165-84.
18. Schechter, A.L., Hung, M.C., Vaidyanathan, L. et al. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985, 229: 976-8.
19. Alroy, I., Yarden, Y. The erbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410: 83-6.
20. Pinkas-Kramarski, R., Soussan, L., Waterman, H. et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996, 15: 2452-67.
21. Lemmon, M.A., Schlessinger, J. Regulation of signal transduction and signal diversity by receptor oligomerization. TIBS 1994, 19: 459-63.
22. Scott, G.K., Dodson, J.M., Montgomery, P.A. et al. p185HER2 signal transduction in breast cancer cells. J Biol Chem 1991, 266: 14300-5.
23. Aasland, R., Lillehaug, J.R., Male, R., Josendal, O., Varhaug, J.E., Kleppe, K. Expression of oncogenes in thyroid tumors: Co-expression of c-erbB2/neu and c-erbB. Br J Cancer 1988, 57: 358-63.
24. Yokota, J., Yamamoto, T., Toyoshima, K. et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986, 1: 765-7.
25. Venter, D.J., Tuzi, N.L., Kumar, S., Gullick, W.J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification. Lancet 1987, 2: 69-72.
26. Pauletti, G., Godolphin, W., Press, M.F., Slamon, D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996, 13: 63-72.
27. Tzahar, E., Waterman, H., Chen, X. et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16: 5276-87.
28. Holmes, W.E., Sliwkowski, M.X., Akita, R.W. et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992, 256: 1205-10.
29. Lupu, R., Colomer, R., Kannan, B., Lippman, M.E. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 1992, 89: 2287-91.
30. Sliwkowski, M.X., Schaefer, G., Akita, R.W. et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994, 269: 14661-5.
31. Karunagaran, D., Tzahar, E., Beerli, R.R. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 1996, 15: 254-64.
32. Albanell, J., Bellmunt, J., Molina, R. et al. Node-negative breast cancers with p53(-)/ HER2-neu(-) status may identify women with very good prognosis. Anticancer Res 1996, 16: 1027-32.
33. Guy, C.T., Webster, M.A., Schaller, M., Parsons, T.J., Cardiff, R.D., Muller, W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992, 89: 10578-82.
34. Fendly, B.M., Winget, M., Hudziak, R.M., Lipari, M.T., Napier, M.A., Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990, 50: 1550-8.
35. McKenzie, S.J., Marks, P.J., Lam, T. et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989, 4: 543-8.
36. Stancovski, I., Hurwitz, E., Leitner, D., Ullrich, A., Yarden, Y., Sela, M. Mechanistic aspects of the 23 opposing effects of monoclonal antibodies to the erbB-2 receptor on tumor growth. Proc Natl Acad Sci USA 1991, 88: 8691-5.
37. Kasprzyk, P.G., Song, S.U., Di Fiore, P.P., King, C.R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992, 52: 2771-6.
38. Hancock, M.C., Langton, B.C., Chan, T. et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diammine-dichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991, 51: 4575-80.
39. Lewis, G.D., Lofgren, J.A., McMurtrey, A.E. et al. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996, 56: 1457-65.
40. Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M., Ullrich, A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989, 9: 1165-72.
41. Kern, J.A., Torney, L., Weiner, D., Gazdar, A., Shepard, H.M., Fendly, B. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol 1993, 9: 448-54.
42. Carter, P., Presta, L., Gorman, C.M. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89: 4285-9.
43. Pegram, M.D., Baly, D., Wirth, C. et al. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of a humanized anti-HER2 antibody. Proc Am Assoc Cancer Res 1997, 38: A4044.
44. Baly, D.L., Wirth, C.M., Allison, D.A., Hotaling, T.E., Fox, J.A. Development and characterization of a rhuMAb HER2 antibody assay for clinical evaluation of cytotoxic potency. Proc Am Assoc Cancer Res 1997, 38: A181.
45. Tokuda, Y., Ohnishi, Y., Shimamura, K. et al. In vitro and in vivo anti-tumor effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996, 73: 1362-5.
46. Kumar, R., Shepard, H.M., Mendelsohn, J. Regulation of phosphorylation of the c-erbB-2/ HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 1991, 11: 979-86.
47. Sarup, J.C., Johnson, R.M., King, K.L. et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991, 1: 72-82.
48. Klapper, L.N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., Sela, M. A subclass of tumor-inhibitory monoclonal antibodies to erbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997, 14: 2099-109.
49. Reese, D., Arboleda, J., Twaddell, J., Akita, R., Sliwkowski, M., Slamon, D. Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells. Proc Am Assoc Cancer Res 1996, 37: A353.
50. Petit, A.M., Rak, J., Hung, M.C. et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151: 1523-30.
51. Benz, C.C., Scott, G.K., Sarup, J.C. et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24: 85-95.
52. Scott, G.K., Robles, R., Park, J.W. et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993, 13: 2247-57.
53. Zabrecky, J.R., Lam, T., McKenzie, S.J., Carney, W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991, 266: 1716-20.
54. Lin, Y.L., Clinton, G.M. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991, 6: 639-43.
55. Pupa, S.M., Menard, S., Morelli, D., Pozzi, B., De Palo, G., Colnaghi, M. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993, 8: 2917-23.
56. Brodowicz, T., Wiltschke, C., Budinsky, A.C., Krainer, M., Steger, G.G., Zielinski, C.C. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997, 73: 875-9.
57. Leitzel, K., Teramoto, Y., Konrad, K. et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormonal therapy of breast cancer. J Clin Oncol 1995, 13: 1129-235.
58. Yamauchi, H., O'Neill, A., Gelman, R. et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein, J Clin Oncol 1996, 15: 18-25.
59. Harris, L.N., Trock, B., Berris, M. et al. The role of ErbB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 1996, 15: A96.
60. Baselga, J., Tripathy, D., Mendelsohn, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-44.
61. Pegram, M.D., Lipton, A., Hayes, D.F. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 16: 2659-71.
62. Cobleigh, M.A., Vogel, C.L., Tripathy, D. et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998, 17: A376.
63. Arteaga, C.L., Carty-Dugger, T., Winnier, A.R. Antibodies against p185HER2 enhance etoposide induced cytotoxicity against human breast carcinoma cells. Proc Am Soc Clin Oncol 1993, 12: A103.
64. Pietras, R.J., Pegrani, M.D., Finn, R.S., Maneval, D.A., Slamon, D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17: 2235-49.
65. Pietras, R.J., Fendly, B.M., Chazin, V.R., Pegram, M.D., Howell, S.D., Slamon, D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9: 1829-38.
66. Arteaga, C.L., Winnier, A.R., Poirier, M.C. et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994, 54: 3758-65.
67. Seidman, A.D. Chemotherapy for advanced breast cancer: A current perspective. Semin Oncol 1996, 23: 55-9.
68. Harris, J.R., Morrow, M., Norton, L. Malignant tumors of the breast. In: Cancer: Principles & Practice of Oncology, 5th Ed. DeVita, V.T. (Ed.). Lippincott-Raven: Philadelphia 1997, 1557-616.
69. Baselga, J., Norton, L., Coplan, K., Shalaby, R., Mendelsohn, J. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 1994, 35: A2262.
70. Baselga, J., Norton, L., Masui, H. et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993, 85: 1327-33.
71. Bos, M., Mendelsohn, J., Bowden, D. et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc Am Soc Clin Oncol 1996, 15: A443.
72. Ueno, N.T., Yu, D., Hung, M.C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997, 15: 953-60.
73. Zhang, L., Hung, M.C. Sensitization of HER-2/ neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 1996, 12: 571-6.
74. neu expressing non-small cell lung cancer cells. Cancer Res 1996, 56: 1068-74.
75. WAF1 and p53 requires c-raf-1. Cancer Res 1995, 55: 4623-6.
76. cdc2 kinase. Mol Cell 1998, 2: 581-91.
77. Slamon, D., Leyland-Jones, B., Shak, S. et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998, 17: A377.
78. Vogel, C.L., Cobleigh, M.A., Tripathy, D. et al. Efficacy and safety of Herceptin (trastuzumab, humanized anti-HER2 antibody) as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer (HER2+/ MBC). Breast Cancer Res Treat 1998, 50: A23.
79. Seidman, A.D., Hudis, C.A., Albanell, J. et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16: 3353-61.